aTyr Pharma Future Growth

NasdaqCM:ATYR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	43	-60	-65	-145	7
12/31/2025	4	-68	-57	-58	7
12/31/2024	0	-67	-58	-76	6
9/30/2024	0	-64	-67	-67	N/A
6/30/2024	1	-58	-64	-63	N/A
3/31/2024	1	-54	-58	-55	N/A
12/31/2023	0	-50	-37	-33	N/A
9/30/2023	11	-43	-38	-33	N/A
6/30/2023	10	-45	-40	-35	N/A
3/31/2023	10	-45	-35	-32	N/A
12/31/2022	10	-45	-44	-42	N/A
9/30/2022	N/A	-46	-40	-40	N/A
6/30/2022	N/A	-41	-39	-39	N/A
3/31/2022	N/A	-39	-38	-37	N/A
12/31/2021	N/A	-34	-33	-33	N/A
9/30/2021	2	-30	-31	-30	N/A
6/30/2021	2	-29	-25	-24	N/A
3/31/2021	2	-25	-23	-23	N/A
12/31/2020	10	-16	-16	-15	N/A
9/30/2020	9	-17	-15	-15	N/A
6/30/2020	9	-16	-14	-14	N/A
3/31/2020	8	-16	-12	-12	N/A
12/31/2019	0	-24	-20	-20	N/A
9/30/2019	0	-24	-20	-20	N/A
6/30/2019	0	-25	-22	-22	N/A
3/31/2019	N/A	-30	-27	-27	N/A
12/31/2018	N/A	-35	-32	-31	N/A
9/30/2018	N/A	-40	-37	-37	N/A
6/30/2018	N/A	-44	N/A	-39	N/A
3/31/2018	N/A	-45	N/A	-39	N/A
12/31/2017	N/A	-48	N/A	-42	N/A
9/30/2017	N/A	-49	N/A	-44	N/A
6/30/2017	N/A	-52	N/A	-50	N/A
3/31/2017	N/A	-55	N/A	-54	N/A
12/31/2016	N/A	-58	N/A	-53	N/A
9/30/2016	N/A	-62	N/A	-51	N/A
6/30/2016	N/A	-59	N/A	-46	N/A
3/31/2016	N/A	-55	N/A	-43	N/A
12/31/2015	N/A	-48	N/A	-37	N/A
9/30/2015	N/A	-38	N/A	-33	N/A
6/30/2015	N/A	-33	N/A	-29	N/A
3/31/2015	N/A	-28	N/A	-23	N/A
12/31/2014	N/A	-25	N/A	-23	N/A
9/30/2014	N/A	-24	N/A	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATYR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ATYR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATYR is expected to become profitable in the next 3 years.

Revenue vs Market: ATYR's revenue (80.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ATYR's revenue (80.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATYR's Return on Equity is forecast to be high in 3 years time

aTyr Pharma Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 8.8% to US$24.60

Consensus revenue estimates decrease by 85%, EPS upgraded

Consensus revenue estimates fall by 70%

Forecast to breakeven in 2026

Consensus revenue estimates fall by 93%

Consensus EPS estimates upgraded to US$0.90 loss

Recent updates

New minor risk - Financial position

New minor risk - Profitability

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

New minor risk - Share price stability

Independent Director recently bought US$185k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021